The company is coming back into the spotlight thanks to recent developments.
InvestorsHub on MSN
BioNTech shares fall after BMO downgrade and price target cut
BioNTech SE (NASDAQ:BNTX) shares fell 1.2% to $102.55 in premarket trading after BMO Capital downgraded the stock and reduced ...
The company also recently earned regulatory approval in the U.S. for mFLUSIVA, an influenza vaccine, a niche where it should ...
BioNTech SE (NASDAQ:BNTX) is ending a mid-stage study of its personalized mRNA cancer vaccine, autogene cevumeran, after an ...
BioNTech SE and Roche Holding AG abandoned a trial of a personalized cancer vaccine, dashing hopes that had been raised by a ...
BioNTech's colorectal cancer vaccine just collapsed in a Phase 2 trial, dragging Moderna down with it despite last week's ...
Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would ...
BioNTech and Genentech elect to end their Phase II trial of autogene Cevumeran after DSMB identified a numerical overall ...
BioNTech (NasdaqGS:BNTX) named Dr. Guido Oelkers as incoming CEO, marking a major leadership transition at the company. The European Commission approved BioNTech’s updated COVID-19 vaccine formula ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results